IDEXX Laboratories stock slides 1.21% and underperforms competitors
Updated
Updated · MarketWatch · May 7
IDEXX Laboratories stock slides 1.21% and underperforms competitors
8 articles · Updated · MarketWatch · May 7
The shares closed at $572.20 on Thursday as the S&P 500 fell 0.38% to 7,337.11 and the Dow dropped 0.63% to 49,596.97.
IDEXX ended 25.69% below its 52-week high of $769.98 reached on 26 November. Johnson & Johnson fell 0.94%, while Medtronic and Boston Scientific rose.
Trading volume reached 638,883 shares, above the 50-day average of 543,456, during a broadly weak market session that left IDEXX lagging parts of the healthcare sector.
As analysts predict a 26% upside, what major headwind is causing IDEXX stock to currently underperform?
With strong earnings but a falling stock, is IDEXX a market bargain or a leadership transition risk?
Can a breakthrough cancer test for dogs shield IDEXX from broader market downturns and fewer vet visits?